Tamoxifen for early breast cancer: An overview of the randomised trials
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Practice Guidelines as Topic
For women with tumours that have been reliably shown to be ER-negative, adjuvant tamoxifen remains a matter for research. However, some years of adjuvant tamoxifen treatment substantially improves the 10-year survival of women with ER-positive tumours and of women whose tumours are of unknown ER status, with the proportional reductions in breast cancer recurrence and in mortality appearing to be largely unaffected by other patient characteristics or treatments.